2 completed, 2 terminated. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 2 |
| Phase 1 | 2 | Terminated 2 |
Follow CureTech Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma CT-011, Rituximab - Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 32 | 2010-01-01 | 2016-06-03 |
| Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma CT-011 - Primary Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | CureTech Ltd | 2 | 2009-10-01 | 2012-10-23 |
| Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection CT-011 - Chronic Hepatitis C | Phase 1 / Phase 2 | Terminated | CureTech Ltd | 13 | 2009-09-01 | 2014-08-29 |
| CT-011 MAb in DLBCL Patients Following ASCT CT-011 - Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse | Phase 2 | Completed | CureTech Ltd | 72 | 2007-10-01 | 2014-09-12 |
Carcinoma, Hepatocellular (1) · Hepatitis C, Chronic (1) · Liver Diseases (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Recurrence (1)
pidilizumab (4) · Rituximab (1)
Israel (3) · United States (2) · India (1)
Yaron Ilan, MD (2) · Arnon Nagler, MD (1) · Leo I Gordon, MD (1) · Sattva S. Neelapu, MD (1)